Odylia Therapeutics will be discussing our RPGRIP1 Gene Therapy program to treat vision loss in patients diagnosed with Leber Congenital Amaurosis 6 (LCA6). Join us to learn more about Odylia Therapeutics and the progress of our gene therapy program, as well as next steps. Meeting details: Tuesday,...
Odylia is looking forward to helping the SATB2 Gene Foundation further SATB2 research through this new partnership....
“We are very excited to have Tainsen join the Odylia Advisory Board,” said Scott Dorfman, Odylia Therapeutics’ CEO....
Odylia and Foundation Fighting Blindness are hosting a 4-part preclinical and translational research webinar series. The series will focus on genetic technologies and will provide advice and educational materials to researchers in the rare disease space. If you are currently working in or thinking about preclinical...
Converting vertical information approaches into horizontal solutions for all members of the rare disease community....
Dr. Winslow will oversee scientific operations and strategy development with a focus on expanding partnerships....
Dr. Robinson brings extensive biotech experience in gene therapy, ophthalmology and more...
Atlanta, GA August 6, 2019 – Emil Kakkis, MD, PhD, joins the Board of Directors for Odylia Therapeutics. Kakkis is the CEO, President and Founder of Ultragenyx Pharmaceutical Inc., which is committed to developing and commercializing treatments for multiple rare and ultra-rare diseases. He brings to Odylia vast knowledge...
SOUTH PLAINFIELD, N.J., and BOSTON, M.A. - July 1, 2019 – PTC Therapeutics, Inc. (NASDAQ: PTCT) and Odylia Therapeutics today announced a strategic collaboration to develop novel gene therapies in rare inherited retinal diseases (IRDs) utilizing the Anc80 vector system developed by researchers at Massachusetts...